We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is EW Stock Worth Buying as Growth Clashes With a Premium Valuation?
Read MoreHide Full Article
Key Takeaways
EW's Q2 revenues rose 13.6%, while adjusted earnings increased 16.4% to 78 cents per share.
EW raised 2026 TAVR growth guidance to 8-9% and companywide sales growth guidance to 10-11%.
EW trades at 28.78 times forward earnings, above its sub-industry, sector and S&P 500 benchmarks.
Edwards Lifesciences Corporation (EW - Free Report) is entering the second half of 2026 with faster structural heart growth and better operating leverage. Second-quarter revenues rose 13.6% to $1.74 billion, while adjusted earnings increased 16.4% to 78 cents per share.
The question is whether that momentum warrants a premium valuation. TAVR and TMTT are expanding, but foreign exchange, litigation, reimbursement dependence and competition raise the hurdle for further upside.
EW’s Growth Profile Is Getting Stronger
Second-quarter adjusted operating income rose 20.8% to $522.7 million, and adjusted operating margin expanded 180 basis points to 30%. Revenue growth outpaced operating-expense growth enough to produce meaningful earnings leverage.
TAVR sales totaled $1.26 billion, up 10.5% at constant currency. Management raised 2026 TAVR constant-currency growth guidance to 8-9% from 7-9% and lifted companywide constant-currency sales growth guidance to 10-11% from 9-11%. The Zacks Consensus Estimate projects 2026 company revenue growth of 11.1%.
Edwards’ TMTT Portfolio Expands the Opportunity
Transcatheter Mitral and Tricuspid Therapies sales reached $195.9 million in the second quarter, up 44.8% at constant currency. PASCAL, EVOQUE and SAPIEN M3 all contributed ahead of management’s expectations as adoption broadened across mitral and tricuspid procedures.
Management raised 2026 TMTT sales guidance to $760-$780 million from $740-$780 million and continues to target $2 billion in TMTT revenues by 2030. That faster-growing platform gives Edwards a second major avenue alongside its much larger TAVR franchise.
Based on short-term price targets offered by 27 analysts, the average price target for Edwards Lifesciences comes to $101.78. The average price target represents an increase of 9.38% from the last closing price.
Image Source: Zacks Investment Research
EW’s Premium Valuation Raises the Bar
EW trades at a forward 12-month price-to-earnings ratio of 28.78, compared with 27.25 for the Zacks sub-industry, 21.15 for the Zacks sector and 20.66 for the S&P 500. Its five-year median is 30, so the stock is not far from its own longer-term norm despite trading above broader benchmarks.
The premium matters because large medical-device peers are still investing aggressively. Abbott Laboratories (ABT - Free Report) reported 9% second-quarter 2026 Medical Devices sales growth, while Boston Scientific Corporation (BSX - Free Report) posted 8.3% growth in cardiovascular sales. Those results reinforce the competitive intensity surrounding high-growth cardiovascular markets.
Edwards Faces Margin and Execution Risks
Adjusted gross margin was 77.6% in the second quarter, unchanged year over year, as lower manufacturing expenses offset a roughly 70-basis-point foreign-exchange headwind. Management expects 2026 gross margin near the lower end of its 78%-79% range.
Litigation, tariffs and reimbursement add execution uncertainty. Edwards also expects its 2026 tax rate at the high end of the prior 16-19% range and faces intense competition as a prior competitor-exit benefit rolls off in Europe. Sustaining differentiation in SAPIEN and newer structural heart platforms remains important.
In the past year, EW shares rose 18.4% outperforming the industry’s 3.2% decline.
Image Source: Zacks Investment Research
EW’s Growth Score Supports a Patient Approach
The investment case remains balanced. Edwards has expanding structural heart opportunities, improving operating leverage and ample liquidity, but its valuation already reflects a meaningful growth premium and leaves less room for execution setbacks for investors considering new positions.
EW currently carries a Zacks Rank #3 (Hold). Its Growth Score of A supports the strength of its growth characteristics, but a Value Score of D and Momentum Score of F temper the setup. The VGM Score of C points to a mixed profile across value, growth and momentum. Because Zacks Style Scores are designed to complement the Zacks Rank, this combination favors patience rather than treating growth alone as a sufficient buy signal.
View the Zacks #1 Rank List
Image: Bigstock
Is EW Stock Worth Buying as Growth Clashes With a Premium Valuation?
Key Takeaways
Edwards Lifesciences Corporation (EW - Free Report) is entering the second half of 2026 with faster structural heart growth and better operating leverage. Second-quarter revenues rose 13.6% to $1.74 billion, while adjusted earnings increased 16.4% to 78 cents per share.
The question is whether that momentum warrants a premium valuation. TAVR and TMTT are expanding, but foreign exchange, litigation, reimbursement dependence and competition raise the hurdle for further upside.
EW’s Growth Profile Is Getting Stronger
Second-quarter adjusted operating income rose 20.8% to $522.7 million, and adjusted operating margin expanded 180 basis points to 30%. Revenue growth outpaced operating-expense growth enough to produce meaningful earnings leverage.
TAVR sales totaled $1.26 billion, up 10.5% at constant currency. Management raised 2026 TAVR constant-currency growth guidance to 8-9% from 7-9% and lifted companywide constant-currency sales growth guidance to 10-11% from 9-11%. The Zacks Consensus Estimate projects 2026 company revenue growth of 11.1%.
Edwards’ TMTT Portfolio Expands the Opportunity
Transcatheter Mitral and Tricuspid Therapies sales reached $195.9 million in the second quarter, up 44.8% at constant currency. PASCAL, EVOQUE and SAPIEN M3 all contributed ahead of management’s expectations as adoption broadened across mitral and tricuspid procedures.
Management raised 2026 TMTT sales guidance to $760-$780 million from $740-$780 million and continues to target $2 billion in TMTT revenues by 2030. That faster-growing platform gives Edwards a second major avenue alongside its much larger TAVR franchise.
Based on short-term price targets offered by 27 analysts, the average price target for Edwards Lifesciences comes to $101.78. The average price target represents an increase of 9.38% from the last closing price.
Image Source: Zacks Investment Research
EW’s Premium Valuation Raises the Bar
EW trades at a forward 12-month price-to-earnings ratio of 28.78, compared with 27.25 for the Zacks sub-industry, 21.15 for the Zacks sector and 20.66 for the S&P 500. Its five-year median is 30, so the stock is not far from its own longer-term norm despite trading above broader benchmarks.
The premium matters because large medical-device peers are still investing aggressively. Abbott Laboratories (ABT - Free Report) reported 9% second-quarter 2026 Medical Devices sales growth, while Boston Scientific Corporation (BSX - Free Report) posted 8.3% growth in cardiovascular sales. Those results reinforce the competitive intensity surrounding high-growth cardiovascular markets.
Edwards Faces Margin and Execution Risks
Adjusted gross margin was 77.6% in the second quarter, unchanged year over year, as lower manufacturing expenses offset a roughly 70-basis-point foreign-exchange headwind. Management expects 2026 gross margin near the lower end of its 78%-79% range.
Litigation, tariffs and reimbursement add execution uncertainty. Edwards also expects its 2026 tax rate at the high end of the prior 16-19% range and faces intense competition as a prior competitor-exit benefit rolls off in Europe. Sustaining differentiation in SAPIEN and newer structural heart platforms remains important.
In the past year, EW shares rose 18.4% outperforming the industry’s 3.2% decline.
Image Source: Zacks Investment Research
EW’s Growth Score Supports a Patient Approach
The investment case remains balanced. Edwards has expanding structural heart opportunities, improving operating leverage and ample liquidity, but its valuation already reflects a meaningful growth premium and leaves less room for execution setbacks for investors considering new positions.
EW currently carries a Zacks Rank #3 (Hold). Its Growth Score of A supports the strength of its growth characteristics, but a Value Score of D and Momentum Score of F temper the setup. The VGM Score of C points to a mixed profile across value, growth and momentum. Because Zacks Style Scores are designed to complement the Zacks Rank, this combination favors patience rather than treating growth alone as a sufficient buy signal.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.